Reducing the rate and duration of Re-ADMISsions among patients with unipolar disorder and bipolar disorder using smartphone-based monitoring and treatment - the RADMIS trials: study protocol for two randomized controlled trials

Maria Faurholt-Jepsen, Mads Frost, Klaus Martiny, Nanna Tuxen, Nicole Rosenberg, Jonas Busk, Ole Winther, Jakob Eyvind Bardram, Lars Vedel Kessing, Maria Faurholt-Jepsen, Mads Frost, Klaus Martiny, Nanna Tuxen, Nicole Rosenberg, Jonas Busk, Ole Winther, Jakob Eyvind Bardram, Lars Vedel Kessing

Abstract

Background: Unipolar and bipolar disorder combined account for nearly half of all morbidity and mortality due to mental and substance use disorders, and burden society with the highest health care costs of all psychiatric and neurological disorders. Among these, costs due to psychiatric hospitalization are a major burden. Smartphones comprise an innovative and unique platform for the monitoring and treatment of depression and mania. No prior trial has investigated whether the use of a smartphone-based system can prevent re-admission among patients discharged from hospital. The present RADMIS trials aim to investigate whether using a smartphone-based monitoring and treatment system, including an integrated clinical feedback loop, reduces the rate and duration of re-admissions more than standard treatment in unipolar disorder and bipolar disorder.

Methods: The RADMIS trials use a randomized controlled, single-blind, parallel-group design. Patients with unipolar disorder and patients with bipolar disorder are invited to participate in each trial when discharged from psychiatric hospitals in The Capital Region of Denmark following an affective episode and randomized to either (1) a smartphone-based monitoring system including (a) an integrated feedback loop between patients and clinicians and (b) context-aware cognitive behavioral therapy (CBT) modules (intervention group) or (2) standard treatment (control group) for a 6-month trial period. The trial started in May 2017. The outcomes are (1) number and duration of re-admissions (primary), (2) severity of depressive and manic (only for patients with bipolar disorder) symptoms; psychosocial functioning; number of affective episodes (secondary), and (3) perceived stress, quality of life, self-rated depressive symptoms, self-rated manic symptoms (only for patients with bipolar disorder), recovery, empowerment, adherence to medication, wellbeing, ruminations, worrying, and satisfaction (tertiary). A total of 400 patients (200 patients with unipolar disorder and 200 patients with bipolar disorder) will be included in the RADMIS trials.

Discussion: If the smartphone-based monitoring system proves effective in reducing the rate and duration of re-admissions, there will be basis for using a system of this kind in the treatment of unipolar and bipolar disorder in general and on a larger scale.

Trial registration: ClinicalTrials.gov, ID: NCT03033420 . Registered 13 January 2017. Ethical approval has been obtained.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and outcome assessments in the RADMIS trials
Fig. 2
Fig. 2
Flow diagram of the RADMIS trials
Fig. 3
Fig. 3
The Monsenso self-assessment system. Screenshot of the smartphone-based self-assessment
Fig. 4
Fig. 4
The Monsenso self-assessment system. Screenshot of the smartphone-based self-assessment of mood

References

    1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–52. doi: 10.1001/archpsyc.64.5.543.
    1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (ncs-r) JAMA. 2003;289(23):3095–105. doi: 10.1001/jama.289.23.3095.
    1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86. doi: 10.1016/S0140-6736(13)61611-6.
    1. Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B. on behalf of the CDBE2010 study group, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62. doi: 10.1111/j.1468-1331.2011.03590.x.
    1. Arbejdsgruppe under Regeringens udvalg om Psykiatri. Indsatsen for mennesker med psykiske lidelser- kapacitet, sammenhæng og strktur. Bilagsrapport 1. Afrapportering fra Arbejdsgruppemøde under Regeringens udvalg om Psykiatri. 2013.
    1. The Psychiatric Central Register. [Internet]. 2016. Available from: . Accessed 11 June 2017.
    1. Mortensen PB, Agerbo E, Erikson T, Qin P, Westergaard-Nielsen N. Psychiatric illness and risk factors for suicide in Denmark. Lancet Lond Engl. 2000;355(9197):9–12. doi: 10.1016/S0140-6736(99)06376-X.
    1. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. Br J Psychiatry. 2004;185:372–7. doi: 10.1192/bjp.185.5.372.
    1. Kessing LV, Hansen HV, Hvenegaard A, Christensen EM, Dam H, Gluud C, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202(3):212–9. doi: 10.1192/bjp.bp.112.113548.
    1. Nørregaard L, Løventoft P, Frøkjær E, Lauritsen L, Olsson E, Andersen L, et al. Patient expectations and experiences from a clinical study in psychiatric care using a self-monitoring system. In: NordiCHI’14: Proceedings of the 8th Nordic Conference on Human-Computer Interaction: Fun, Fast, Foundational. Helsinki: Association for Computing Machinery; 2014. p. 991–4.
    1. Faurholt-Jepsen M, Frost M, Vinberg M, Christensen EM, Bardram JE, Kessing LV. Smartphone data as objective measures of bipolar disorder symptoms. Psychiatry Res. 2014;217(1–2):124–7. doi: 10.1016/j.psychres.2014.03.009.
    1. Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram JE, Kessing LV. Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar Disord. 2015;17(7):715–28. doi:10.1111/bdi.12332.
    1. Faurholt-Jepsen M. Behavioral activities collected through smartphones and the association with illness activity in bipolar disorder. Int J Methods Psychiatr Res. 2016. In press
    1. Bardram J, Frost M, Szanto K, Margu G. The MONARCA self-assessment system: a persuasive personal monitoring system for bipolar patients. In: Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium (IHI’12) ACM, New York, NY, USA, 21-30. ACM New York, NY, USA; 2012. p. 21–30.
    1. Faurholt-Jepsen M, Vinberg M, Christensen EM, Frost M, Bardram J, Kessing LV. Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder—the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open. 2013;3(7). doi:10.1136/bmjopen-2013-003353.
    1. Watts SE, Turnell A, Kladnitski N, Newby JM, Andrews G. Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression. J Affect Disord. 2015;175:152–67. doi: 10.1016/j.jad.2014.12.025.
    1. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry J Ment Sci. 2006;188:313–20. doi: 10.1192/bjp.188.4.313.
    1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–7. doi: 10.1001/archpsyc.59.6.530.
    1. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–62. doi: 10.1176/appi.ajp.2013.13020185.
    1. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60(2):145–52. doi: 10.1001/archpsyc.60.2.145.
    1. Lam DH, Hayward P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry. 2005;162(2):324–9. doi: 10.1176/appi.ajp.162.2.324.
    1. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry. 2007;164(9):1340–7. doi: 10.1176/appi.ajp.2007.07020311.
    1. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ. 1999;318(7177):149–53. doi: 10.1136/bmj.318.7177.149.
    1. Simon GE, Ludman EJ, Bauer MS, Unützer J, Operskalski B. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry. 2006;63(5):500–8. doi: 10.1001/archpsyc.63.5.500.
    1. Scott J, Colom F. Gaps and limitations of psychological interventions for bipolar disorders. Psychother Psychosom. 2008;77(1):4–11.
    1. Watkins ER. Depressive rumination: investigating mechanisms to improve cognitive behavioural treatments. Cogn Behav Ther. 2009;38(S1):8–14. doi: 10.1080/16506070902980695.
    1. Ebert DD, Zarski A-C, Christensen H, Stikkelbroek Y, Cuijpers P, Berking M, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. PLoS ONE [Internet]. 2015;10(3). Available from: . Accessed on 4 Feb 2016.
    1. Ly KH, Janni E, Wrede R, Sedem M, Donker T, Carlbring P, et al. Experiences of a guided smartphone-based behavioral activation therapy for depression: a qualitative study. Internet Interv. 2015;2(1):60–8. doi: 10.1016/j.invent.2014.12.002.
    1. Morriss RK, Faizal MA, Jones AP, Williamson PR, Bolton C, McCarthy JP. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev. 2007;1:CD004854.
    1. Burns MN, Begale M, Duffecy J, Gergle D, Karr CJ, Giangrande E, et al. Harnessing context sensing to develop a mobile intervention for depression. J Med Internet Res. 2011;13(3):e55. doi: 10.2196/jmir.1838.
    1. Doryab A. Detection of behavior change in people with depression. In: Workshops at the Twenty Eighth AAAI Conference. 2014.
    1. Bardram JE, Frost M, Szánto K, Faurholt-Jepsen M, Vinberg M, Kessing LV. Designing mobile health technology for bipolar disorder: a field trial of the Monarca system. In: Proceedings of the SIGCHI Conference on Human Factors in Computing Systems. CHI: New York; 2013. p. 2627–36.
    1. Faurholt-Jepsen M, Frost M, Ritz C, Christensen EM, Jacoby AS, Mikkelsen RL, et al. Daily electronic self-monitoring in bipolar disorder using smartphones—the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. Psychol Med. 2015;29:1–14.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. doi: 10.1192/bjp.133.5.429.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. doi: 10.1136/bmj.c869.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295–309. doi: 10.7326/0003-4819-148-4-200802190-00008.
    1. Chan A-W, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–2. doi: 10.1016/S0140-6736(12)62160-6.
    1. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47(6):589–93. doi: 10.1001/archpsyc.1990.01810180089012.
    1. Malig C. The civil registration system in Denmark. Rockville pike, Bethesda: Princeton University Library: International Institute for Vital Registration and Statistics; 1996.
    1. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82–4.
    1. Martell CR, Dimidjian S, Herman-Dunn R. Behavioral activation for depression: a clinician’s guide. New York: The Guilford Press; 2010.
    1. Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif. 2001;25(2):255–86. doi: 10.1177/0145445501252005.
    1. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658–70. doi: 10.1037/0022-006X.74.4.658.
    1. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of depression: a meta-analysis. Clin Psychol Rev. 2007;27(3):318–26. doi: 10.1016/j.cpr.2006.11.001.
    1. Dobson KS, Hollon SD, Dimidjian S, Schmaling KB, Kohlenberg RJ, Gallop R, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468–77. doi: 10.1037/0022-006X.76.3.468.
    1. Dimidjian S, BarreraJr M, Martell C, Muñoz RF, Lewinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol. 2011;7(1):1–38. doi: 10.1146/annurev-clinpsy-032210-104535.
    1. Ly KH, Trüschel A, Jarl L, Magnusson S, Windahl T, Johansson R, et al. Behavioural activation versus mindfulness-based guided self-help treatment administered through a smartphone application: a randomised controlled trial. BMJ Open [Internet]. 2014;4(1). Available from: . Accessed 13 June 2016.
    1. Ly KH, Topooco N, Cederlund H, Wallin A, Bergström J, Molander O, et al. Smartphone-supported versus full behavioural activation for depression: a randomised controlled trial. PLoS ONE [Internet]. 2015;10(5). Available from: . Accessed 13 June 2016.
    1. Shen GH, Alloy LB, Abramson LY, Sylvia LG. Social rhythm regularity and the onset of affective episodes in bipolar spectrum individuals. Bipolar Disord. 2008;10(4):520–9. doi: 10.1111/j.1399-5618.2008.00583.x.
    1. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy vs. medications for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9(10):788–96. doi: 10.1038/nrn2345.
    1. Watts S, Mackenzie A, Thomas C, Griskaitis A, Mewton L, Williams A, et al. CBT for depression: a pilot RCT comparing mobile phone vs. computer. BMC Psychiatry. 2013;13:49. doi: 10.1186/1471-244X-13-49.
    1. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278–96. doi: 10.1111/j.2044-8260.1967.tb00530.x.
    1. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health CP EMH. 2007;3:5. doi: 10.1186/1745-0179-3-5.
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385–96. doi: 10.2307/2136404.
    1. WHO Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28(3):551–8. doi: 10.1017/S0033291798006667.
    1. Bech P, Olsen LR. Discovering depression. Ugeskr Laeger. 2001;163(14):1980–2.
    1. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66(2–3):159–64. doi: 10.1016/S0165-0327(00)00309-8.
    1. Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med. 2003;33(2):351–6. doi: 10.1017/S0033291702006724.
    1. Bech P, Gefke M, Lunde M, Lauritzen L, Martiny K. The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: a double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. Depress Res Treat [Internet]. 2011;2011. Available from: . Accessed 22 Mar 2016.
    1. Corrigan PW, Salzer M, Ralph RO, Sangster Y, Keck L. Examining the factor structure of the Recovery Assessment Scale. Schizophr Bull. 2004;30(4):1035–41. doi: 10.1093/oxfordjournals.schbul.a007118.
    1. Rogers ES, Chamberlin J, Ellison ML, Crean T. A consumer-constructed scale to measure empowerment among users of mental health services. Psychiatr Serv Wash DC. 1997;48(8):1042–7. doi: 10.1176/ps.48.8.1042.
    1. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–7. doi: 10.1016/S0920-9964(99)00130-9.
    1. Bech P, Olsen LR, Kjoller M, Rasmussen NK. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-being Scale. Int J Methods Psychiatr Res. 2003;12(2):85–91. doi: 10.1002/mpr.145.
    1. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–95. doi: 10.1016/0005-7967(90)90135-6.
    1. Kessing LV, Hansen HV, Ruggeri M, Bech P. Satisfaction with treatment among patients with depressive and bipolar disorders. Soc Psychiatry Psychiatr Epidemiol. 2006;41(2):148–55. doi: 10.1007/s00127-005-0012-4.
    1. Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J, Kessing LV. The effects of centralised and specialised intervention in the early course of severe unipolar depressive disorder: a randomised clinical trial. PloS One. 2012;7(3):e32950. doi:10.1371/journal.pone.0032950.
    1. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359(9306):614–8. doi: 10.1016/S0140-6736(02)07750-4.
    1. Schulz KF, Grimes DA. Unequal group sizes in randomised trials: guarding against guessing. Lancet. 2002;359(9310):966–70. doi: 10.1016/S0140-6736(02)08029-7.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit